Trial · NCT06158269
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
NCT06158269, Phase 2, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma. Trials, record NCT06158269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06158269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
- NCT number
- NCT06158269
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Multiple Myeloma
- Interventions
- DVRd
- First posted
- 2023-12-06
- Last updated
- 2023-12-06
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MRD negative rate | through study completion, an average of 3 year | MRD detected by next generation sequencing |
| Secondary | Duration of negative MRD | through study completion, an average of 3 year | From the first record of negative MRD to the first record of positive MRD or the end of follow-up, whichever came first, assessed up to 3 year |
| Secondary | stringent complete response (sCR) | through study completion, an average of 3 year | stringent complete response |
| Secondary | ORR | through study completion, an average of 3 year | Overall response rate (ORR): Complete response (CR) + Very good partial response (VGPR) + Partial response (PR) |
| Secondary | Duration of response (DOR) | through study completion, an average of 3 year | The duration from the first record of achieving at least PR to the occurrence of progressive disease (PD) or death caused by PD, whichever occurs at first |
| Secondary | Mobilization success rate | after all patients accepted stem cell mobilization, an average of 1.5 year | Mobilization success rate, high-quality mobilization rate and poor-quality mobilization |
| Secondary | Progression-free survival (PFS) | through study completion, an average of 3 year | From date of enrollment of patients until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 year |
| Secondary | Overall survival (OS) | through study completion, an average of 3 year | From date of enrollment of patients until the date of death from any cause, whichever came first, assessed up to 3 year |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06158269
GET https://conductscience.org/api/trials/v1/NCT06158269/registered